Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress
–179% year-over-year revenue increase driven by record sales of consumables and growth in the Saphyr installed base
–All 2021 milestones on track
–Strong balance sheet with $362 million cash as of March 31, 2021
–Conference call today, Thursday, May 13, at 4:30 pm ET
SAN DIEGO, May 13, 2021 – Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the first quarter ended March 31, 2021 and highlighted recent corporate updates.
“2021 is off to a solid start for Bionano. In the first quarter, we sold a record number of flow cells, analyzed a record number of samples in our service lab, drove broad adoption of Saphyr instruments and ramped up the installation of Saphyr systems that weren’t yet operational because of 2020’s travel restrictions,” said Erik Holmlin, PhD, CEO of Bionano. “With the largest number of Saphyr systems in service analyzing more genomes than ever before, we are seeing a sharp increase in the quality and scale of studies that are being published and presented and the awareness they build. The power of optical genome mapping, or OGM, data was on display at our own Next-Generation Cytogenomics Symposium, and through our strong presence at various key conferences in the US, Europe and China we continued to drive the awareness we believe is needed to develop the market for structural variation analysis and OGM. In Q1 2021 we saw a clear expansion into new geographical areas and into new applications such as prenatal analysis, cancer research and drug development. Our customers continued development of Saphyr-based assays for structural variation analysis in our key growth areas of prenatal and post-natal genetics, hematologic malignancies and solid tumors in Europe, the US, Canada and new markets across the world. As our customers grow the number of laboratory-developed tests (LDTs) in the market, we expect this will build out the path to reimbursement of Saphyr-based LDTs by third party payers in the US and around the world.”
Chris Stewart, Chief Financial Officer of Bionano added, “In the quarter, we solidified our foundation for growth through two successful financings, contributing to a cash position of $362 million as of the end of the quarter. We anticipate that the strength of our balance sheet will enable us to clear barriers to global adoption of OGM with Saphyr, support applications development to open up additional end-user markets and drive toward the next wave of big biology and innovation in genomics.”

Key Business Highlights
The Company executed on its commercialization strategy, continued to build scientific momentum by presenting data at key scientific meetings, and drove utilization of Saphyr® at key institutions across the globe, with the following notable announcements:
•Hosted the Next-Generation Cytogenomics symposium, which featured distinguished speakers from around the globe describing how OGM could be applied to clinical research and discovery research in pre-natal and postnatal genetic diseases, hematologic malignancies, solid tumors and host genome COVID research.
•Expanded into new geographic markets including South Africa, Greece, Russia, South Korea, and important clinical sites in the United Kingdom and Germany
◦King’s College Hospital in London and the NHS Regional Genetics Laboratory in Belfast City Hospital adopted Saphyr systems.
•Gained Saphyr adoption by the University Health Network in Toronto, which has the largest hospital diagnostic lab in Canada.
•Dr Jim Broach at Penn State University published a method for solid tumor analysis by OGM, unlocking the largest oncology market for Saphyr.
•Dr Yuval Ebenstein at Tel Aviv University published a method to analyze DNA methylation in cancer genomes, enabling a new field of cancer research and drug target discovery.
•Praxis Genomics obtained DEX Z-codes from Palmetto MolDX for billing in connection with the performance of their whole genome analysis LDT for constitutional genetic disease.
•Increased the speed of our compute on demand cloud computing solution by 30% and reduced the cost to the end-user by 50%.
•MD Anderson Cancer Center published a study showing how Saphyr significantly reduced the time to results for myelodysplastic syndrome from weeks to 4 days.
•Dr Gordana Raca from Children’s Hospital in Los Angeles presented results showing that Saphyr detects druggable gene fusions in pediatric acute leukemias that next-generation sequencing and cytogenetics missed.
•Developed new applications for Saphyr in the field of prenatal testing with publications, presentations, and the adoption of Saphyr by the Foundation for Embryonic Competence; and in cancer research and drug development with several publications on DNA methylation and DNA replication.

•Bionano customers presented a record number of presentations across all four of Bionano’s main target growth markets - prenatal, postnatal/constitutional genetics, blood cancers and solid tumor analysis – with Optical Genome Mapping (OGM) at the 2021 Annual Clinical Genetics Meeting of ACMG. We believe these publications and presentations demonstrate the utility of OGM across our targeted markets.
•Strengthened the balance sheet by raising approximately $337 million from two underwritten public offerings of shares of its common stock, the utilization of its $40 million ATM facility, and the exercise of outstanding warrants, enabling the company to advance the business without near term capital constraints.
Financial Highlights
•Total revenue was $3.2 million for the three months ended March 31, 2021, up 179% from $1.1 million in the same period of 2020. Revenue increased in all regions. The increase in product sales was driven by increased demand of our reagent rental program and consumables, while the increase in service revenue was primarily driven by sales from our Lineagen subsidiary.
•Gross margin for the first quarter of 2021 was 33%, up 8% from 25% in the same period in 2020. The increase was primarily due to a shift in our product mix toward higher margin consumables and services.
•Operating expense for the first quarter of 2021 was $12.2 million, an increase of approximately $2.2 million compared to $10.0 million for the same period in 2020. The change is primarily due to increased headcount and material and supply expense, offset by a $1M decrease in bad debt expense.
•At March 31, 2021, the Company had cash and cash equivalents of $362 million compared to cash and cash equivalents of $38.4 million at December 31, 2020. The increase in cash is due to the equity raises that were completed in January 2021.
•A gain on debt extinguishment of $1.8 million was recognized during the three months ended March 31, 2020 due to the forgiveness in full of our PPP loan, including all accrued interest.
Upcoming Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr
2Q21: Accreditation of Saphyr based LDTs for ALL & FSHD in certain EU markets
3Q21: Commercial release of prenatal assays and expansion of the menu of pediatric assays

4Q21: Interim publication of results from pediatric clinical study
4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study
4Q21: Initial prototype of next gen high throughput Saphyr
4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020
Conference Call & Webcast Details

Date: | Thursday, May 13, 2021
Time: | 4:30 p.m. Eastern Time
Toll Free: | (833) 397-0959
International: | (614) 999-1719
Conference ID: | 7163806
Webcast: | https://edge.media-server.com/mmc/p/5hjudqv7

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential reimbursement of LDTs based on Saphyr; our cash position and its potential impact on our ability to execute our operational objectives; our anticipated milestones for the rest of 2021; and the advancement of our business strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; our inability to achieve the anticipated benefits from our acquisition of Lineagen; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS |
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations and
Media Contact:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com

Bionano Genomics, Inc.
Condensed Consolidated Balance Sheet (Unaudited)
| (Unaudited) |  |
| March 31, 2021 |  | December 31, 2020
Assets |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 362,057,000 |  |  | $ | 38,449,000 |
Accounts receivable, net | 1,992,000 |  |  | 2,775,000 |
Inventory | 3,036,000 |  |  | 3,316,000 |
Prepaid expenses and other current assets | 3,166,000 |  |  | 2,250,000 |
Total current assets | 370,251,000 |  |  | 46,790,000 |
Property and equipment, net | 5,806,000 |  |  | 4,910,000 |
Intangible Assets | 1,396,000 |  |  | 1,475,000 |
Goodwill | 7,173,000 |  |  | 7,173,000 |
Other Long Term Assets | $ | 235,000 |  |  | $ | 103,000 |
Total assets | $ | 384,861,000 |  |  | $ | 60,451,000 |
Liabilities and stockholders’ equity |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 2,209,000 |  |  | $ | 2,930,000 |
Accrued expenses | 4,659,000 |  |  | 5,599,000 |
Contract liabilities | 301,000 |  |  | 416,000 |
Total current liabilities | 7,169,000 |  |  | 8,945,000 |
Long-term debt, net of current portion | 14,866,000 |  |  | 16,326,000 |
Long-term contract liabilities | 108,000 |  |  | 98,000 |
Total liabilities | 22,143,000 |  |  | 25,369,000 |
Stockholders’ equity: |  |  |
Common stock | 28,000 |  |  | 19,000 |
Additional paid-in capital | 516,321,000 |  |  | 178,747,000 |
Accumulated deficit | (153,631,000) |  |  | (143,684,000) |
Total stockholders’ equity | 362,718,000 |  |  | 35,082,000 |
Total liabilities and stockholders’ equity | $ | 384,861,000 |  |  | $ | 60,451,000 |

Bionano Genomics, Inc. |  |  |  |
Condensed Consolidated Statement of Operations |  |  |  |
| Three Months Ended March 31, |  |
| 2021 |  | 2020 |  |  |  |
Revenue: |  |  |  |  |  |  |
Product revenue | $ | 2,049,000 |  |  | $ | 983,000 |  |  |  |  |
Service and other revenue | 1,119,000 |  |  | 153,000 |  |  |  |  |
Total revenue | 3,168,000 |  |  | 1,136,000 |  |  |  |  |
Cost of revenue: |  |  |  |  |  |  |
Cost of product revenue | 1,513,000 |  |  | 774,000 |  |  |  |  |
Cost of service and other revenue | 612,000 |  |  | 82,000 |  |  |  |  |
Total cost of revenue | 2,125,000 |  |  | 856,000 |  |  |  |  |
Operating expenses: |  |  |  |  |  |  |
Research and development | 2,678,000 |  |  | 2,674,000 |  |  |  |  |
Selling, general and administrative | 9,528,000 |  |  | 7,368,000 |  |  |  |  |
Total operating expenses | 12,206,000 |  |  | 10,042,000 |  |  |  |  |
Loss from operations | (11,163,000) |  |  | (9,762,000) |  |  |  |  |
Other income (expenses): |  |  |  |  |  |  |
Interest expense | (538,000) |  |  | (761,000) |  |  |  |  |
Gain on debt extinguishment | 1,775,000 |  |  | — |  |  |  |  |
Other income (expenses) | (15,000) |  |  | 18,000 |  |  |  |  |
Total other income (expenses) | 1,222,000 |  |  | (743,000) |  |  |  |  |
Loss before income taxes | (9,941,000) |  |  | (10,505,000) |  |  |  |  |
Provision for income taxes | (6,000) |  |  | (5,000) |  |  |  |  |
Net loss | $ | (9,947,000) |  |  | $ | (10,510,000) |  |  |  |  |